Tillkännagivande • Mar 20
Pila Pharma AB (publ), Annual General Meeting, May 19, 2026 Pila Pharma AB (publ), Annual General Meeting, May 19, 2026, at 15:00 W. Europe Standard Time. Tillkännagivande • Dec 23
Pila Pharma AB (publ) to Report First Half, 2026 Results on Aug 27, 2026 Pila Pharma AB (publ) announced that they will report first half, 2026 results on Aug 27, 2026 Tillkännagivande • Dec 20
Pila Pharma AB (publ) Initiates the Planned Preclinical Studies in Obesity Pila Pharma AB (publ) announced that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary clinical drug candidate XEN-D0501 in rats with obesity. During July, PILA PHARMA completed a rights issue of units to make "a bet on obesity" by demonstrating proof-of-concept in obesity. First in rats, and then in humans. Initially it was planned to use the same oral formulation that was successfully used in the 13-week tox study in normal rats, previously conducted by PILA PHARMA. However, it has been decided to use a formulation well known by Gubra to ensure the best fit to dosing obese rats. The readout of the rat studies are confirmed to be on track and results communicated prior to the TO2 warrant exercise period. The net proceeds from the warrants are intended to finance clinical trials of PILA PHARMA' clinical development candidate XEN-D051 in obesity. Tillkännagivande • Oct 29
Pila Pharma AB (publ) announced that it has received SEK 30 million in funding Pila Pharma AB (publ) announced private placement of common shares for gross proceeds of SEK 30,000,000 on October 28, 2025. The subscription rate was 293.5% meaning that investors have wanted to invest more than the company had initially offered. Tillkännagivande • Sep 04
Pila Pharma AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026 Pila Pharma AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026 Tillkännagivande • Dec 19
Pila Pharma AB (Publ) Announces Preclinical Preclinical Proof-Of-Concept Achieved in Cardiometabolic Diseases PILA PHARMA AB (publ) announced the completion of the study of the Research Group of Professor Dick Wagsater, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice. The aim of the preclinical study was to establish a pre-clinical proof-of-concept of that the TRPV1 antagonist XEN-D0501 could decrease Abdominal Aneurysm growth In mice. The headline study results show that XEN-D0501 had a robust decrease in aorta dilatation of more than 50% compared to placebo, which was the goal. It almost completely inhibited aneurysm development in this pre-clinical model, thus, establishing proof-of-concept. Pending a confirmatory study, the data will be published and presented in a scientific outlet. XEN-D0501 is a selective, synthetic potent small molecule TRPV1 antagonist that was in-licensed in 2016. TRPV1 antagonists that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. Prior to in-licensing, XEN-D051 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D051 is well tolerated by in people living with obesity and type 2 diabetes. Further, PP-CT02, demonstrated that XEN-D0701 (administered as 4 mg bidaily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. Furthermore, ANP, a cardiovascular biomarker for heart failure, was highly statistically significantly reduced. During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. Currently, a scientific advice regarding the study design of the next clinical phase 2a trial, PP-CT03, is being prepared and will be followed by a clinical trial submission in the UK. The objective of the study is to identify the maximal tolerable dose of XEN-D051 in people living with obesity and Type 2 diabetes and to evaluate the safety profile following 3 months chronic treatment. In addition to the safety assessment, PP-CT03 will also include sufficient participants that should allow for efficacy readouts on reduction of body weight. Tillkännagivande • Nov 14
PILA PHARMA AB (publ) Announces Selection of Clinical Trial Site and Decision to Seek Scientific Advice for Optimized PP-CT03 Study Design PILA PHARMA AB (publ) announced the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical trial site for the conduct of PP-CT03 as well as the as having decided to seek further scientific advice as first step. On 17 October, PILA PHARMA informed of optimization changes to the trial plan for PP-CT03 plan, due mainly to internal safety concerns of running the trial at a non-hospital site, as well as the decision to conduct at least the initial part at a hospital site. The company has now selected the scientific advisor to PILA PHARMA, Professor Mark Evans, as principal investigator of the study and the Cambridge University Hospital, UK, as the principal trial site of PP-CT03. Furthermore, following discussions with Professor Evans, it has been decided to seek scientific advice with the UK MRHA prior to clinical trial application. The objective is to further strengthen the PP-CT03 study design and increase the opportunity for this study to provide input to a clear development and regulatory plan in diabetes and potentially obesity. Reported Earnings • Aug 28
First half 2024 earnings released First half 2024 results: Revenue: kr683.0k (down 38% from 1H 2023). Net loss: kr4.09m (loss narrowed 42% from 1H 2023). Tillkännagivande • Apr 24
Pila Pharma AB (publ) to Report First Half, 2024 Results on Aug 27, 2024 Pila Pharma AB (publ) announced that they will report first half, 2024 results on Aug 27, 2024 Reported Earnings • Feb 29
Full year 2023 earnings released: kr0.54 loss per share (vs kr1.55 loss in FY 2022) Full year 2023 results: kr0.54 loss per share (improved from kr1.55 loss in FY 2022). Revenue: kr1.46m (down 22% from FY 2022). Net loss: kr9.93m (loss narrowed 63% from FY 2022). Tillkännagivande • Dec 06
Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million. Pila Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 8.07888 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,385,920
Price\Range: SEK 1.5
Transaction Features: Rights Offering Reported Earnings • Oct 28
Third quarter 2023 earnings released Third quarter 2023 results: Net loss: kr1.53m (loss narrowed 74% from 3Q 2022). Reported Earnings • Aug 23
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr301.0k (down 54% from 2Q 2022). Net loss: kr3.06m (loss narrowed 53% from 2Q 2022). Board Change • Aug 04
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director of the Board Richard Busellato was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 27
First quarter 2023 earnings released: kr0.22 loss per share (vs kr0.64 loss in 1Q 2022) First quarter 2023 results: kr0.22 loss per share (improved from kr0.64 loss in 1Q 2022). Revenue: kr796.0k (up 49% from 1Q 2022). Net loss: kr4.04m (loss narrowed 61% from 1Q 2022). Board Change • Feb 23
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jan 30
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Aug 22
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Aug 05
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Milan Zdravkovic was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jul 02
Pila Pharma AB (Publ) Announces the Preclinical Toxicological Three-Month Studies of the Active Substance Xen-D0501 Has Begun Pila Pharma AB (publ) announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical trials in humans with up to one month doses with very good safety results, indicating that the molecule is very well tolerated. The new preclinical toxicological studies aims to confirm the safety of the duration of the forthcoming phase 2b study, i.e three months. Board Change • May 10
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Director Gudmund Korsgard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Tillkännagivande • Apr 26
Pila Pharma AB Announces Certification of API Pila Pharma AB announced that the study material to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety studies was outsourced to Almac Group. This production has now been completed as Almac has verified that the final product complies with the specifications and has issued a certificate of analysis. This in turn means that Pila Pharma's development of a new diabetes drug is going according to plan, and that the company can now proceed towards the planned longer preclinical studies that are necessary to be able to carry out a clinical phase 2b study. 